Conference Paper: A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses

File Download

re01.htm

Links for fulltext
(May Require Subscription)

Publisher Website: 10.1556/EuJMI.1.2011.2.1
Find via

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Microbiology: Conference papers

Title	A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses
Authors	Du, L Leung, VHC Jiang, S Zheng, B
Keywords	Influenza A virus H5N1 Hemagglutinin Recombinant vaccine Cross-protection
Issue Date	2011
Publisher	Akademiai Kiado Rt.. The Journal's web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology
Citation	The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11 [How to Cite?] DOI: http://dx.doi.org/10.1556/EuJMI.1.2011.2.1
Abstract	Development of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.
Description	Poster abstracts - Session D: Viral Infections and Vaccines
ISSN	2062-509X
DOI	http://dx.doi.org/10.1556/EuJMI.1.2011.2.1

DC Field	Value
dc.contributor.author	Du, L
dc.contributor.author	Leung, VHC
dc.contributor.author	Jiang, S
dc.contributor.author	Zheng, B
dc.date.accessioned	2011-07-27T02:00:10Z
dc.date.available	2011-07-27T02:00:10Z
dc.date.issued	2011
dc.description.abstract	Development of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.
dc.description.nature	link_to_OA_fulltext
dc.description	Poster abstracts - Session D: Viral Infections and Vaccines
dc.description.other	The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11
dc.identifier.citation	The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11 [How to Cite?] DOI: http://dx.doi.org/10.1556/EuJMI.1.2011.2.1
dc.identifier.doi	http://dx.doi.org/10.1556/EuJMI.1.2011.2.1
dc.identifier.epage	182
dc.identifier.hkuros	188738
dc.identifier.issn	2062-509X
dc.identifier.issue	2
dc.identifier.openurl
dc.identifier.spage	182
dc.identifier.uri	http://hdl.handle.net/10722/135939
dc.identifier.volume	1
dc.language	eng
dc.publisher	Akademiai Kiado Rt.. The Journal's web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology
dc.relation.ispartof	European Journal of Microbiology and Immunology
dc.subject	Influenza A virus
dc.subject	H5N1
dc.subject	Hemagglutinin
dc.subject	Recombinant vaccine
dc.subject	Cross-protection
dc.title	A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Du, L</contributor.author><contributor.author>Leung, VHC</contributor.author><contributor.author>Jiang, S</contributor.author><contributor.author>Zheng, B</contributor.author><date.accessioned>2011-07-27T02:00:10Z</date.accessioned><date.available>2011-07-27T02:00:10Z</date.available><date.issued>2011</date.issued><identifier.citation>The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11</identifier.citation><identifier.issn>2062-509X</identifier.issn><identifier.uri>http://hdl.handle.net/10722/135939</identifier.uri><description>Poster abstracts - Session D: Viral Infections and Vaccines</description><description.abstract>Development of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.</description.abstract><language>eng</language><publisher>Akademiai Kiado Rt.. The Journal&apos;s web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology</publisher><relation.ispartof>European Journal of Microbiology and Immunology</relation.ispartof><subject>Influenza A virus</subject><subject>H5N1</subject><subject>Hemagglutinin</subject><subject>Recombinant vaccine</subject><subject>Cross-protection</subject><title>A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses</title><type>Conference_Paper</type><identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=2062-509X&amp;volume=1&amp;issue=2&amp;spage=182, abstract no. D11&amp;epage=&amp;date=2011&amp;atitle=A+recombinant+vaccine+of+H5N1+HA1+fused+with+foldon+and+human+IgG+Fc+induced+complete+cross-clade+protection+against+divergent+H5N1+viruses</identifier.openurl><description.nature>link_to_OA_fulltext</description.nature><identifier.doi>10.1556/EuJMI.1.2011.2.1</identifier.doi><identifier.hkuros>188738</identifier.hkuros><identifier.volume>1</identifier.volume><identifier.issue>2</identifier.issue><identifier.spage>182</identifier.spage><identifier.epage>182</identifier.epage><description.other>The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11</description.other><bitstream.url>http://hub.hku.hk/bitstream/10722/135939/1/re01.htm</bitstream.url></item>